A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Bardoxolone Methyl on Residual Renal Function (RRF) in Patients with End-Stage Renal Disease (ESRD) and Type 2 Diabetes Mellitus (T2DM) on Peritoneal Dialysis (PD)

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Bardoxolone Methyl on Residual Renal Function (RRF) in Patients with End-Stage Renal Disease (ESRD) and Type 2 Diabetes Mellitus (T2DM) on Peritoneal Dialysis (PD)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2012

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Renal failure; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to withdrawn prior to recruitment, as reported in a Reata Pharmaceuticals media release.
    • 21 Jul 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-001563-78).
    • 03 Jul 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top